106 related articles for article (PubMed ID: 22976922)
1. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
[TBL] [Abstract][Full Text] [Related]
2. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.
Armstrong TS; Wen PY; Gilbert MR; Schiff D
Neuro Oncol; 2012 Oct; 14(10):1203-14. PubMed ID: 22307472
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
[TBL] [Abstract][Full Text] [Related]
4. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab.
Avery RA; Hwang EI; Jakacki RI; Packer RJ
JAMA Ophthalmol; 2014 Jan; 132(1):111-4. PubMed ID: 24232489
[TBL] [Abstract][Full Text] [Related]
5. Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
Kalra M; Heath JA; Kellie SJ; Dalla Pozza L; Stevens MM; Swamy S; McCowage GB
J Pediatr Hematol Oncol; 2015 Aug; 37(6):e341-6. PubMed ID: 26056795
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Fangusaro J; Gururangan S; Poussaint TY; McLendon RE; Onar-Thomas A; Warren KE; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Kun LE; Fouladi M
Cancer; 2013 Dec; 119(23):4180-7. PubMed ID: 24104527
[TBL] [Abstract][Full Text] [Related]
7. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
[TBL] [Abstract][Full Text] [Related]
8. Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma.
Zhukova N; Rajagopal R; Lam A; Coleman L; Shipman P; Walwyn T; Williams M; Sullivan M; Campbell M; Bhatia K; Gottardo NG; Hansford JR
Cancer Med; 2019 Jan; 8(1):40-50. PubMed ID: 30569607
[TBL] [Abstract][Full Text] [Related]
9. Optic pathway gliomas: a review.
Fried I; Tabori U; Tihan T; Reginald A; Bouffet E
CNS Oncol; 2013 Mar; 2(2):143-59. PubMed ID: 25057976
[TBL] [Abstract][Full Text] [Related]
10. Single agent carboplatin for pediatric low-grade glioma: A retrospective analysis shows equivalent efficacy to multiagent chemotherapy.
Dodgshun AJ; Maixner WJ; Heath JA; Sullivan MJ; Hansford JR
Int J Cancer; 2016 Jan; 138(2):481-8. PubMed ID: 26235348
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: a systematic review and meta-analysis of outcome rates.
Lu VM; Welby JP; Nesvick CL; Daniels DJ
Neurooncol Pract; 2020 Jul; 7(4):359-368. PubMed ID: 33282324
[TBL] [Abstract][Full Text] [Related]
12. Visual Deficits and Diagnostic and Therapeutic Strategies for Neurofibromatosis Type 1: Bridging Science and Patient-Centered Care.
Miyagishima KJ; Qiao F; Stasheff SF; Nadal-Nicolás FM
Vision (Basel); 2024 May; 8(2):. PubMed ID: 38804352
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of bevacizumab in treatment of recurrent low-grade glioma: a systematic review and meta-analysis.
Habibi MA; Rashidi F; Gharedaghi H; Arshadi MR; Kazemivand S
Eur J Clin Pharmacol; 2024 May; ():. PubMed ID: 38733390
[TBL] [Abstract][Full Text] [Related]
14. Glioma.
Weller M; Wen PY; Chang SM; Dirven L; Lim M; Monje M; Reifenberger G
Nat Rev Dis Primers; 2024 May; 10(1):33. PubMed ID: 38724526
[TBL] [Abstract][Full Text] [Related]
15. The Present and Future of Optic Pathway Glioma Therapy.
Dal Bello S; Martinuzzi D; Tereshko Y; Veritti D; Sarao V; Gigli GL; Lanzetta P; Valente M
Cells; 2023 Sep; 12(19):. PubMed ID: 37830595
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis type1, type 2, tuberous sclerosis and Von Hippel-Lindau disease.
Elbeltagy M; Abbassy M
Childs Nerv Syst; 2023 Oct; 39(10):2791-2806. PubMed ID: 37819506
[TBL] [Abstract][Full Text] [Related]
17. Optic Pathway Gliomas: The Trends of Basic Research to Reduce the Impact of the Disease on Visual Function.
Bianchi F; Cocilovo FM; Ruggiero A; Tamburrini G
Adv Tech Stand Neurosurg; 2023; 48():123-137. PubMed ID: 37770684
[TBL] [Abstract][Full Text] [Related]
18. Benign Glioma.
Wu PB; Filley AC; Miller ML; Bruce JN
Adv Exp Med Biol; 2023; 1405():31-71. PubMed ID: 37452934
[TBL] [Abstract][Full Text] [Related]
19. Intralesional Bevacizumab as Adjuvant Therapy for Juvenile Onset Recurrent Respiratory Papillomatosis: A Systematic Review.
Guragain R; Gyawali BR
Indian J Otolaryngol Head Neck Surg; 2023 Jun; 75(2):1296-1301. PubMed ID: 37275063
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
